Welcome to our dedicated page for ASP Isotopes news (Ticker: ASPI), a resource for investors and traders seeking the latest updates and insights on ASP Isotopes stock.
ASP Isotopes Inc. develops isotope enrichment technologies and related critical-materials businesses for nuclear medicine, next-generation semiconductors, nuclear energy and helium markets. Company news commonly covers its Aerodynamic Separation Process and Quantum Enrichment platforms, enrichment facilities in Pretoria, South Africa, and target isotopes such as Silicon-28, Carbon-14 and Ytterbium-176.
Recurring updates also address PET Labs radiopharmaceutical operations, Quantum Leap Energy nuclear fuel-cycle initiatives, lithium laser enrichment research, Renergen and the Virginia Gas Project, material agreements, governance matters, capital-structure disclosures, and operating and financial results.
ASP Isotopes (NASDAQ: ASPI) subsidiary Quantum Leap Energy entered a non-binding MOU with a large U.S. energy company to evaluate support for U.S.-based advanced nuclear fuel facilities. The facilities are planned to produce HALEU, LEU+, and provide conversion/deconversion services to strengthen the domestic supply chain.
QLE said the MOU outlines potential financial support terms tied to definitive supply agreements and anticipates technical diligence and pathways toward long-term commercial collaboration.
ASP Isotopes (NASDAQ: ASPI) announced that Quantum Leap Energy appointed Dr. Nate Salpeter as Chief Technology Officer on March 5, 2026. Dr. Salpeter brings over 15 years of experience building computational and experimental programs at TerraPower, Kairos Power, and other organizations.
He will focus on optimizing in-licensed and proprietary technologies, standing up computational and experimental frameworks, implementing rapid learning cycles, and leading disciplined de-risking to advance QLE's commercialization objectives.
ASP Isotopes (NASDAQ: ASPI) announced that a South African subsidiary of Quantum Leap Energy executed a Services Contract on Feb 20, 2026 with the South African Nuclear Energy Corporation (Necsa) to advance research, design and potential commercial production of HALEU at Necsa's Pelindaba site.
The agreement provides QLE SA access to facilities, infrastructure and services for siting, design, construction, commissioning and operation, establishes a Joint Coordination Committee, and is subject to Necsa site rules and required National Nuclear Regulator approvals.
ASP Isotopes (NASDAQ: ASPI) said on Feb 19, 2026 that its wholly owned subsidiary Quantum Leap Energy (QLE) formed a Strategic Advisory Board and appointed Mary Lou Dunzik-Gougar and Kevin Kramer as initial members.
QLE will advise on nuclear fuel cycle gaps while developing proprietary isotope enrichment technologies including the ASP aerodynamic process and laser-based Quantum Enrichment (QE) to target cost, safety, and supply-chain improvements for fission and fusion fuel applications.
ASP Isotopes (NASDAQ: ASPI) said its wholly owned subsidiary Quantum Leap Energy will establish global headquarters in Austin, Texas, expanding QLE’s U.S. presence and operational plans. QLE plans a significant Texas footprint and to advance a joint venture with Fermi America tied to HALEU enrichment and isotope production.
QLE and ASPI plan facilities affiliated with Fermi America’s Amarillo hypergrid campus, aligning with DOE estimates of rising HALEU demand through 2035–2050.
ASP Isotopes (NASDAQ: ASPI) provided a production update on the Renergen Helium Project after completing its January 6, 2026 acquisition of Renergen. Since operations restarted in April 2025, management reports ~60% higher gas throughput, 15 gas intersections (~80% drilling success), ~60% of Phase 1 LNG contracted, and ongoing plant commissioning aimed at positive operational cash flow before end-2026.
Upgrades include a new compressor station, cold-box modifications, CO2 scrubber, gas-gathering >70% complete, and additional drilling and evaluation of a newly identified shallow sandstone reservoir.
ASP Isotopes (Nasdaq: ASPI) closed its acquisition of Renergen on January 7, 2026, creating a combined company focused on isotope production and liquid helium supply for semiconductors, quantum computing and clean energy.
Key financing includes a prior $40 million U.S. DFC finance agreement and expected debt facilities totaling $750 million (a $500 million senior DFC facility and a $250 million Standard Bank facility) to expand helium production at the Virginia Gas project. The company approved 700,000 inducement shares for two Renergen executives with four-year vesting. A Virtual Investor Update is planned for late January.
ASP Isotopes (NASDAQ: ASPI) announced it has obtained all required regulatory approvals for its proposed acquisition of JSE-listed Renergen via a South African scheme of arrangement.
Renergen shareholders will receive 0.09196 ASP Isotopes shares per Renergen share. The scheme is unconditional and implementation awaits a compliance certificate from the South African Takeover Regulation Panel, anticipated on or about December 18, 2025. Final dates will follow the certificate.
The combination targets an integrated supply chain for helium, LNG, fluorinated products and isotopically enriched gases, with synergies expected from 2026. A production update on Renergen’s Virginia Gas Project is expected at the end of January 2026. Renergen is noted as being funded by the U.S. government for helium’s strategic significance.
ASP Isotopes (NASDAQ: ASPI) announced that founder and Executive Chairman Paul Mann will resume his role as Chief Executive Officer, effective January 19, 2026, while continuing as Executive Chairman.
Mr. Mann had taken a temporary leave of absence from CEO duties for health reasons on September 29, 2025; during his leave, Chief Operating Officer Robert Ainscow served as Interim CEO and will return to his COO role when Mr. Mann resumes full day‑to‑day CEO duties. Mr. Mann said he has engaged with shareholders and intends to focus on long‑term value creation and strengthened execution frameworks for 2026.
ASP Isotopes (NASDAQ: ASPI) announced a three-year donation to establish a new Photonics Chair at the University of Witwatersrand (Wits) in Johannesburg, with Dr. Angela Dudley named as the inaugural chair.
The endowment will support the Structured Light Laboratory in Wits’ School of Physics, fund photonics research and development, and aim to produce a pipeline of students and candidates for ASP Isotopes as the company scales its quantum enrichment programme.